Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma, Inc. will host a conference call and webcast on November 9, 2023, to provide a business and clinical update. The company will discuss the progress of its Phase 1 trials for CUE-101 and CUE-102, its IL-2 based biologics for the treatment of head and neck cancer and WT1 expressing cancers. Additional clinical, pipeline, and business updates will also be addressed. Positive data from the clinical programs will be presented at the SITC 2023 Annual Meeting.

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will host a conference call and webcast to provide a business and clinical update on Thursday, November 9, 2023 at 4:30 p.m. ET. Live and archived versions of the event can be accessed via the Company’s website.

The Company will provide a clinical update from its Phase 1 trials evaluating the lead interleukin 2 (IL-2)-based biologic, CUE-101, as monotherapy and in combination with KEYTRUDA^® (pembrolizumab) for patients with recurrent/metastatic HPV+ head and neck cancer and from the ongoing Phase 1 trial with the Company’s second IL-2 based candidate, CUE-102, for the treatment of Wilms’ Tumor 1 (WT1) expressing cancers. Additional clinical, pipeline and business updates will also be addressed.

As a reminder, posters highlighting new positive data from the CUE-101 and CUE-102 clinical programs will be presented at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) on November 4, 2023.

Webcast Details

Thursday, November 9 at 4:30 p.m. ET

Investors:	1-888-886-7786
International Investors:	1-416-764-8658
Conference ID:	38547752
Request a return call via the Call me™ link:	https://emportal.ink/3RIYunz
		Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time.
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1638430&tp_key=eaa2024234

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com 

Media Contact
Maya Romanchuk
LifeSci Communications
mromanchuk@lifescicomms.com

FAQ

What is the purpose of the conference call and webcast hosted by Cue Biopharma, Inc.?

The purpose of the conference call and webcast is to provide a business and clinical update.

What will Cue Biopharma, Inc. discuss during the conference call and webcast?

Cue Biopharma, Inc. will discuss the progress of its Phase 1 trials for CUE-101 and CUE-102, its IL-2 based biologics for the treatment of head and neck cancer and WT1 expressing cancers. They will also provide additional clinical, pipeline, and business updates.

When will the conference call and webcast take place?

The conference call and webcast will take place on Thursday, November 9, 2023, at 4:30 p.m. ET.

Where can I access the live and archived versions of the event?

The live and archived versions of the event can be accessed via Cue Biopharma, Inc.'s website.

Will there be any presentations of positive data?

Yes, posters highlighting new positive data from the CUE-101 and CUE-102 clinical programs will be presented at the SITC 2023 Annual Meeting on November 4, 2023.